The tweet was deleted by the author.
But we saved everything 🙂.
CVRx has announced its participation in AAHFN2026, where the company will host an interactive dinner symposium focused on the role of Advanced Practice Providers in patient selection and the adoption of Barostim therapy.
Attendees are expected to gain real world insights through case discussions and expert engagement, aiming to support the integration of Barostim into routine clinical practice.
CVRx recently celebrated its 25th Barostim implant at UNC Medical Center Chapel Hill, marking a milestone in its cardiac device therapy program (CVRx Barostim UNC milestone). The company also detailed the methodology for its BENEFIT-HF trial in a newly published peer-reviewed paper (BENEFIT-HF trial published). These initiatives reflect CVRx's ongoing focus on expanding clinical adoption and evidence for Barostim.